指南驱动的药物洗脱支架使用成本效果：倾向评分匹配分析七年多中心经验
基于澳大利亚多中心注册的12,710名PCI患者数据，评估药物洗脱支架在不同适应症数量下的成本效果。
基本信息
资源简介
指南驱动的药物洗脱支架使用成本效果：倾向评分匹配分析七年多中心经验
【一句话概览】
本数据集是 figshare 公开的结构化表格数据集，收录 2 个文件、合计 531.86 KB，主题涵盖 Drug-eluting stents、bare-metal stents、cost-effectiveness、risk factors、guidelines，可用于统计建模、特征工程与队列分析，CC BY 4.0 许可开放获取。
【数据集背景】
本数据集源站标题为《The cost-effectiveness of guideline-driven use of drug-eluting stents: propensity-score matched analysis of a seven-year multicentre experience》。配套论文《The cost-effectiveness of guideline-driven use of drug-eluting stents: propensity-score matched analysis of a seven-year multicentre experience》发表于 Current Medical Research and Opinion（2020），DOI：10.1080/03007995.2019.1708288。源站首次发布：2020-01-20。
【数据内容】
源站原始描述：Background: In routine clinical practice, the implantation of a drug-eluting stent (DES) versus a bare metal stent (BMS) for percutaneous coronary intervention (PCI) has been guided by criteria for appropriate use. The cost-effectiveness (CE) of adopting these guidelines, however, is not clear, and was investigated from the perspective of the Australian healthcare payer. Methods and results: Baseline and 12-month follow-up data of 12,710 PCI patients enrolled in the Melbourne Interventional Grou…
中文译文（机器翻译，仅供快速理解，请以原文为准）：背景：在常规临床实践中，经皮冠状动脉介入治疗（PCI）中植入药物洗脱支架（DES）还是裸金属支架（BMS），一直依据适宜使用标准进行选择。然而，采用这些指南的成本效益（CE）尚不明确，本研究从澳大利亚医疗付费方的角度对此进行了探讨。 方法与结果：分析了2004年至2011年间纳入墨尔本介入组（Melbourne Interventional Group, MIG）注册研究的12,710例PCI患者的基线和12个月随访数据。成本输入来自临床成本核算数据库和已发表文献。在亚组内对DES组和BMS组进行了倾向评分匹配。对所有患者以及具有“0”、1、2或≥3项DES适应证的患者亚组，评估了增量成本效益比（ICER）。在总体人群中，每避免一例靶血管血运重建的增量成本为24,683澳元；在具有0、1和2项DES适应证的患者中，该增量成本分别为44,635澳元、33,335澳元和23,788澳元。然而，对于具有≥3项适应证的患者，与BMS相比，DES与成本节约相关。在45,000–75,000澳元的支付意愿阈值下，DES具有成本效益的概率在总体队列中为71–91%，在“0”项适应证中为49–67%，1项适应证中为56–82%，2项适应证中为70–90%，≥3项适应证中为97–99%。 结论：与BMS相比，DES的成本效益随着患者风险特征的增加而增加，即从具有1项、2项到≥3项DES适应证的患者。与BMS相比，DES在具有“0”项DES适应证的患者中成本效益最低。基于这些结果，支持选择性使用DES植入。这些发现可能有助于循证临床决策。
【数据结构与技术规格】
文件数 2 个，合计 531.86 KB。icmo_a_1708288_sm5187.docx：application/vnd.openxmlformats-officedocument.wordprocessingml.document，456.83 KB。icmo_a_1708288_sm5186.docx：application/vnd.openxmlformats-officedocument.wordprocessingml.document，75.03 KB。数据集 DOI：10.6084/m9.figshare.11447655.v2。
【主题与分类】
源站学科分类：Medicine、Pharmacology、Ecology、Sociology、Cancer、Science Policy。主题标签：Drug-eluting stents、bare-metal stents、cost-effectiveness、risk factors、guidelines、target-vessel revascularisation。
【适用方向】
结构化表格数据可直接用于统计建模、特征工程与队列分析。
【获取与许可】
源站页面：https://tandf.figshare.com/articles/dataset/The_cost-effectiveness_of_guideline-driven_use_of_drug-eluting_stents_propensity-score_matched_analysis_of_a_seven-year_multicentre_experience/11447655
使用许可：CC BY 4.0（https://creativecommons.org/licenses/by/4.0/）。
规范引用：The cost-effectiveness of guideline-driven use of drug-eluting stents: propensity-score matched analysis of a seven-year multicentre experience. Taylor & Francis. Ariyaratne, Thathya V.; Ademi, Zanfina; Ofori-Asenso, Richard; Huq, Molla M.; Duffy, Stephen J.; Yan, Bryan P.; et al
【使用注意】
· 源站最后修改于 2023-05-30，引用时请注意版本时效。
下载信息
注册下载
需要注册 Kaggle 账号并登录后下载，适合需要跟踪下载记录和使用 API 的用户。
暂未开放公开下载
无需注册即可直接获取公开样本或文档，适合快速预览和评估数据集质量。
免登录有偿下载
公开数据集受托下载与技术交付服务。
提供高速下载与技术交付服务（收技术服务费，非数据销售）
暂未开放当前数据集主要来源为 Kaggle 公开托管，完整影像包建议通过原始链接或 Kaggle API 获取。
使用方式
数据集获取（Figshare）
- 源站标题：The cost-effectiveness of guideline-driven use of drug-eluting stents: propensity-score matched analysis of a seven-year multicentre experience
- DOI：10.6084/m9.figshare.11447655.v2
- 发布日期：2020-01-20
- 文件数：2 个
- 文件总体积：531.86 KB
- 源站页面：https://tandf.figshare.com/articles/dataset/The_cost-effectiveness_of_guideline-driven_use_of_drug-eluting_stents_propensity-score_matched_analysis_of_a_seven-year_multicentre_experience/11447655
命令行下载
curl -L -o "icmo_a_1708288_sm5187.docx" "https://ndownloader.figshare.com/files/20414538"
curl -L -o "icmo_a_1708288_sm5186.docx" "https://ndownloader.figshare.com/files/20414541"
文件清单
icmo_a_1708288_sm5187.docx（456.83 KB）icmo_a_1708288_sm5186.docx（75.03 KB）
文件总体积 531.86 KB（源站 API 实测）。
数据加载示例（图像类）
from PIL import Image
import glob, os
files = (glob.glob(os.path.join(path, "**", "*.png"), recursive=True)
+ glob.glob(os.path.join(path, "**", "*.jpg"), recursive=True)
+ glob.glob(os.path.join(path, "**", "*.tif"), recursive=True))
print("图像文件数:", len(files))
img = Image.open(files[0]); print("尺寸/模式:", img.size, img.mode)
# torchvision Dataset 方式:
# from torchvision import datasets
# ds = datasets.ImageFolder(path) # 要求 子目录=类别
目录组织与标注格式以源站说明和下载后实际文件为准。
数据说明
Background: In routine clinical practice, the implantation of a drug-eluting stent (DES) versus a bare metal stent (BMS) for percutaneous coronary intervention (PCI) has been guided by criteria for appropriate use. The cost-effectiveness (CE) of adopting these guidelines, however, is not clear, and was investigated from the perspective of the Australian healthcare payer.
Methods and results: Baseline and 12-month follow-up data of 12,710 PCI patients enrolled in the Melbourne Interventional Group (MIG) registry between 2004 and 2011 were analysed. Costs inputs were derived from a clinical costing database and published sources. Propensity-score-matching was performed for DES and BMS groups within sub-groups. Incremental cost-effectiveness ratios (ICERs) were evaluated for all patients, and sub-groups of patients with ‘0’, 1, 2, or ≥3 indications for a DES. The incremental cost per target vessel revascularization avoided for the overall population was $24,683, and for patients with 0, 1, and 2 indications for a DES was $44,635, $33,335, and $23,788, respectively. However, for those with >3 indications, DES compared with BMS was associated with cost savings. At willingness to pay thresholds of $45,000–$75,000, the probability of cost-effectiveness of DES for the overall cohort was 71–91%, ‘0’ indications, 49–67%, 1 indication, 56–82%, 2 indications, 70–90%, and ≥3 indications, 97–99%.
Conclusions: The cost-effectiveness of DES compared with BMS increased with increasing risk profile of patients from those who had 1, 2, to ≥3 indications for a DES. When compared with BMS, DES was least cost effective among patients with ‘0’ indications for a DES. Based on these results, selective use of DES implantation is supported. These findings may be useful for evidence-based clinical decision-making.
许可
CC BY 4.0
引用
学术使用请引用 DOI 10.6084/m9.figshare.11447655.v2（source: https://tandf.figshare.com/articles/dataset/The_cost-effectiveness_of_guideline-driven_use_of_drug-eluting_stents_propensity-score_matched_analysis_of_a_seven-year_multicentre_experience/11447655）。
数据缺失？
依托陕西、四川两大基地，我们与超过十家三甲医院建立直接合作关系，覆盖合规授权、采集治理、专业标注、数据交付的全流程，为AI医疗团队提供即拿即用的高质量临床数据。
⚡️ 需要数据支持或标注服务？立即联系我们获取专业方案。
